Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Trevi Therapeutics Stock Up 7.3 %
Shares of Trevi Therapeutics stock opened at $6.75 on Monday. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The stock has a market cap of $518.85 million, a price-to-earnings ratio of -15.34 and a beta of 0.90. The company’s fifty day moving average is $4.35 and its 200 day moving average is $3.63.
Insider Transactions at Trevi Therapeutics
In related news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 24.37% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on TRVI
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Articles
- Five stocks we like better than Trevi Therapeutics
- 10 Best Airline Stocks to Buy
- How to Build the Ultimate Everything ETF Portfolio
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.